JP2022500485A - グラピプラント単位剤形 - Google Patents

グラピプラント単位剤形 Download PDF

Info

Publication number
JP2022500485A
JP2022500485A JP2021517311A JP2021517311A JP2022500485A JP 2022500485 A JP2022500485 A JP 2022500485A JP 2021517311 A JP2021517311 A JP 2021517311A JP 2021517311 A JP2021517311 A JP 2021517311A JP 2022500485 A JP2022500485 A JP 2022500485A
Authority
JP
Japan
Prior art keywords
serum
approximately
dosage form
unit dosage
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021517311A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500485A5 (https=
Inventor
マーク マンフレディ，
ジェフリー エクセディ，
厚 長久
貴子 奥村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Askat Inc
Original Assignee
Askat Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Askat Inc filed Critical Askat Inc
Publication of JP2022500485A publication Critical patent/JP2022500485A/ja
Publication of JP2022500485A5 publication Critical patent/JP2022500485A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/2036—Silicones; Polysiloxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021517311A 2018-09-27 2019-09-27 グラピプラント単位剤形 Pending JP2022500485A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862737285P 2018-09-27 2018-09-27
US62/737,285 2018-09-27
US201962834513P 2019-04-16 2019-04-16
US62/834,513 2019-04-16
PCT/US2019/053413 WO2020069288A1 (en) 2018-09-27 2019-09-27 Grapiprant unit dosage forms

Publications (2)

Publication Number Publication Date
JP2022500485A true JP2022500485A (ja) 2022-01-04
JP2022500485A5 JP2022500485A5 (https=) 2022-10-05

Family

ID=69953354

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021517311A Pending JP2022500485A (ja) 2018-09-27 2019-09-27 グラピプラント単位剤形

Country Status (6)

Country Link
US (1) US20210353648A1 (https=)
EP (1) EP3856177A4 (https=)
JP (1) JP2022500485A (https=)
CN (1) CN113260363A (https=)
CA (1) CA3113468A1 (https=)
WO (1) WO2020069288A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021522211A (ja) 2018-04-16 2021-08-30 アリーズ セラピューティクス， インコーポレイテッド Ｅｐ４阻害剤およびその使用
US20210315909A1 (en) 2018-07-11 2021-10-14 Arrys Therapeutics, Inc. Polymorphic compounds and uses thereof
CN115697317A (zh) * 2020-04-08 2023-02-03 株式会社AskAt Ep4受体拮抗剂用于治疗肝癌、黑色素瘤、淋巴瘤和白血病的应用
CN115919756B (zh) * 2022-10-19 2024-08-23 梅州市珍宝金柚实业有限公司 一种金柚原浆口服液及其制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010123049A1 (ja) * 2009-04-22 2010-10-28 ラクオリア創薬株式会社 癌治療のための選択的ｅｐ４受容体拮抗物質
JP2017507190A (ja) * 2014-03-06 2017-03-16 アラタナ セラピューティクス、 インコーポレイテッド グラピプラント組成物およびその使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7998505B2 (en) * 2006-10-27 2011-08-16 Fmc Corporation Dry granulation binders, products, and use thereof
CN103764167A (zh) * 2011-07-15 2014-04-30 尤法玛有限公司 包含抗酸剂、麻醉剂以及含二氧化硅和二氧化钛的无机基质的口服组合物
IN2013MU02370A (https=) * 2013-07-16 2015-06-19 Cadila Pharmaceuticals Ltd

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010123049A1 (ja) * 2009-04-22 2010-10-28 ラクオリア創薬株式会社 癌治療のための選択的ｅｐ４受容体拮抗物質
JP2017507190A (ja) * 2014-03-06 2017-03-16 アラタナ セラピューティクス、 インコーポレイテッド グラピプラント組成物およびその使用方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DRUG TEST ANAL., vol. 10, JPN6023035654, March 2018 (2018-03-01), pages 1237 - 1243, ISSN: 0005316493 *
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, vol. 39, no. 6, JPN6023035655, 2016, pages 566 - 571, ISSN: 0005316492 *
薬物動態試験デザインと投与量比例制の統計的推測方法, JPN7024001853, 2001, ISSN: 0005316494 *

Also Published As

Publication number Publication date
US20210353648A1 (en) 2021-11-18
WO2020069288A1 (en) 2020-04-02
CN113260363A (zh) 2021-08-13
EP3856177A1 (en) 2021-08-04
EP3856177A4 (en) 2022-06-29
CA3113468A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
US12577208B2 (en) TEAD inhibitors and uses thereof
CN116234931B (zh) 对nectin-4具有特异性的双环缀合物及其用途
EP3565638B1 (en) Bicycle conjugate for treating cancer
US20240254120A1 (en) Ep4 inhibitors and synthesis thereof
US20220184222A1 (en) Bicycle toxin conjugates and uses thereof
US12295962B2 (en) Polymorphic compounds and uses thereof
JP2023553866A (ja) Ｔｅａｄ阻害剤、及びその使用
CN109641838A (zh) Cxcr4抑制剂及其用途
CN116133692A (zh) 治疗突变淋巴瘤的方法
WO2023114984A1 (en) Tead inhibitors and uses thereof
JP2022500485A (ja) グラピプラント単位剤形
US11878958B2 (en) MEK inhibitors and uses thereof
WO2023173053A1 (en) Mek inhibitors and uses thereof
US20230233546A1 (en) Methods of treating cancer
EA052011B1 (ru) Бициклические конъюгаты, специфические в отношении нектина-4, и варианты их применения
TW202504912A (zh) 對nectin-4具有專一性之雙環胜肽配體
HK40017381B (en) Bicycle conjugate for treating cancer
HK40017381A (en) Bicycle conjugate for treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220927

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220927

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240229

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240507